SCHEMBL7922281

SCHEMBL7922281

Cc1ccc2c(c1)CC(C)S2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.38
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
HPGD P15428 2/20 0.34
KLK7 P49862 1/20 0.34
AADAT Q8N5Z0 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPC1 O15118 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
METAP1 P53582 2/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7914318 0.84 ACHE (0.42) ACHEKDM4EALDH1A1MEN1KMT2A
SCHEMBL9883346 0.78 NPC1 (0.46) KDM4EALDH1A1MEN1KMT2ABRD4
SCHEMBL12807492 0.78 KDM4E (0.39) KDM4EALDH1A1MEN1KMT2ABRD4
SCHEMBL13937552 0.78 METAP1 (0.34) ACHEAADATSMN1; SMN2METAP1CYP1A2
SCHEMBL12240273 0.77 HTR2C (0.34) ACHEHTR2AHTR2CHTR2B
SCHEMBL13847659 0.76 KDM4E (0.58) ACHEKDM4EALDH1A1HPGDKLK7
SCHEMBL10383073 0.74 KDM4E (0.55) ACHEKDM4EALDH1A1MEN1KMT2A
SCHEMBL12240274 0.74 KDM4E (0.55) ACHEKDM4EALDH1A1MEN1KMT2A
SCHEMBL12993226 0.74 TRPM5 (0.41) ACHEALDH1A1MEN1KMT2ATP53
SCHEMBL24193321 0.73 MAPT (0.39) ACHEKDM4EAADATSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020026975-A1 LIGHT DETECTING ELEMENT AND FINGERPRINT AUTHENTICATING DEVICE 住友化学株式会社 2020-02-06 WO disclosed
US-9959982-B2 Photoelectric conversion element and method for producing the same Konica Minolta, Inc. (JP) 2018-05-01 US disclosed
US-20160155574-A1 PHOTOELECTRIC CONVERSION ELEMENT MODULE AND METHOD FOR MANUFACTURING THE SAME Konica Minolta, Inc. (JP) 2016-06-02 US disclosed
US-20160155574-A1 PHOTOELECTRIC CONVERSION ELEMENT MODULE AND METHOD FOR MANUFACTURING THE SAME Konica Minolta, Inc. (JP) 2016-06-02 US disclosed
EP-2649062-B1 BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) TAKEDA PHARMACEUTICAL (JP) 2015-04-08 EP disclosed
US-8729102-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-05-20 US disclosed
US-8729102-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-05-20 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
WO-2012074126-A9 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-06 WO disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 US disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 US disclosed
WO-2012074126-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 WO disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed
US-20100266556-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2010-10-21 US disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB ACHE 743/4885KDM4E 1415/4885ALDH1A1 762/4885
US-20100266556-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND HCLS1, RUNX1, ACIN1 ACHE 4753/4885KDM4E 2880/4885ALDH1A1 256/4885
US-20120142714-A1 BICYCLIC COMPOUND ACACA, ACACB, FABP4 ACHE 1662/4885KDM4E 1862/4885ALDH1A1 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.